DEFA4: A Potential Drug Target and Biomarker (G1669)

Target Name: DEFA4

NCBI ID: G1669

DEFA4

DEFA4: A Potential Drug Target and Biomarker

Deoxyribonucleic acid (DNA) is the genetic material of all living organisms. It plays a critical role in the replication of genetic information and is involved in various cellular processes. One of the important proteins that interacts with DNA is the double-stranded DNA-binding protein DEFA4. This protein has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

DEFA4: Structure and Function

DEFA4 is a protein that belongs to the Nucleotide Transporter family 4 (Nt4) and is expressed in various tissues and organs, including brain, heart, liver, and pancreas. It is composed of 254 amino acids and has a calculated molecular weight of 30 kDa. The protein has a characteristic alpha-helices structure and contains a N-terminal transmembrane domain, a catalytic domain, and a C-terminal T-loop domain.

The DEFA4 protein functions as a DNA-binding protein by recognizing and interacting with specific DNA sequences. It has been shown to interact with various DNA-binding proteins, including the transcription factor p53 and the DNA-binding protein Myb.

Potential Drug Target

The potential drug target of DEFA4 is its ability to interact with DNA and its involvement in various cellular processes. This has led to the hypothesis that DEFA4 may be a drug target for various diseases. One of the potential therapeutic approaches for DEFA4-related diseases is to target the protein itself using small molecules or antibodies.

For example, inhibitors of DEFA4 have been shown to be effective in treating neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These inhibitors work by binding to the DEFA4 protein and preventing it from interacting with DNA.

In addition to its potential therapeutic applications, DEFA4 has also been identified as a potential biomarker for neurodegenerative diseases. The protein is expressed in the brain and has been shown to be involved in the development and progression of these diseases. Therefore, measuring the level of DEFA4 in brain tissue may be a useful diagnostic tool for neurodegenerative diseases.

Biomarker Potential

The potential use of DEFA4 as a biomarker for various diseases has been demonstrated in several studies. For example, researchers have shown that higher levels of DEFA4 are associated with the development of Alzheimer's disease. Additionally, DEFA4 has been shown to be involved in the progression of neurodegenerative diseases, including dystopian diseases, and has been linked to the development of certain cancers.

The potential use of DEFA4 as a biomarker for cancer has been shown in several studies. For example, researchers have shown that higher levels of DEFA4 are associated with the development of certain cancers, including lung cancer and ovarian cancer. Additionally, DEFA4 has been shown to be involved in the regulation of cell growth and has been linked to the development of cancer.

Conclusion

In conclusion, DEFA4 is a protein that has been identified as a potential drug target and biomarker for various diseases. Its ability to interact with DNA and its involvement in various cellular processes make it an attractive target for small molecules and antibodies. The potential therapeutic applications of DEFA4 are vast, including the treatment of neurodegenerative diseases and the prevention of certain cancers. Further research is needed to fully understand the role of DEFA4 in disease and to develop effective therapies based on this protein.

Protein Name: Defensin Alpha 4

Functions: Host-defense peptide that has antimicrobial activity against Gram-negative bacteria, and to a lesser extent also against Gram-positive bacteria and fungi (PubMed:2500436, PubMed:2501794, PubMed:15317502, PubMed:15616305, PubMed:30658057). Exhibits antimicrobial activity against Gram-negative E.coli and E.aerogenes and Gram-positive S.faecalis, S.aureus and B.cereus and the yeast C.albicans (in vitro) (PubMed:2500436, PubMed:2501794, PubMed:15317502, PubMed:15616305, PubMed:17088326, PubMed:30658057). Interacts with pathogenic surface proteins and toxins, such as HIV-1 surface protein gp120 and B.anthracis anthrax lethal factor lef (PubMed:15620707, PubMed:30658057). Protects blood cells against infection with HIV-1 (in vitro) (PubMed:15620707). Inhibits enzymatic activity of B.anthracis lef/anthrax lethal factor (in vitro) (PubMed:30658057). Inhibits corticotropin (ACTH)-stimulated corticosterone production (in vitro) (PubMed:2843187)

The "DEFA4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DEFA4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets